 |
DoReMi provides an operational tool for the development of the proposed MELODI platform (Multidisciplinary European Low Dose Risk Re-search Initiative) consisting of major national bodies and research programmes that have long term commitment in low dose risk research in Europe. A Letter of Intent between the core members of MELODI has been signed in April 2009. During the project, new members are expected to join the Initiative.
The Joint Programme of Activities (JPA) of DoReMi includes:
- A Joint Programme of Research (JPR) covering the issues outlined above and providing an overview of the needs for research infra-structures of pan-European interest and facilitating multilateral initiatives leading to better use and development of research infrastructures
- A Joint Programme of Integration (JPI) to develop a coor-dinated European roadmap for the long term needs of the key players in Europe
- A Joint Pro-gramme for the Spreading of Excellence (JPSE), covering knowledge management, training and mo-bility and its implementation
The JPR focuses on the areas identified by the HLEG as the most prom-ising in terms of addressing/resolving the key policy questions, namely: the shape of dose response curve for cancer, individual susceptibilities and non-cancer effects. Radiation quality, tissue sensitivity and internal exposures will be addressed as cross cutting themes within the three main research areas. A substantial proportion of the JPA will be dedicated to the joint programme of research. The pro-gramme describes a multidisciplinary approach including interfaces with the broader biological toxico-logical and epidemiological communities. Strategic planning will be carried out in close collaboration with MELODI.
The long term Strategic Research Agenda (SRA) will be developed by MELODI, whereas DoReMi research priorities are based on a shorter term Transitional Research Agenda (TRA), focusing on goals that are feasible to achieve within the 6 year project and areas where barriers need to be removed in order to proceed with the longer term strategic objectives.
Project details:
Start date:2010-01-01
End date:2015-12-31
Project cost: 21.772.358 EURO
Project Funding: 12.999.999 EURO
Programme Acronym: FP7-EURATOM-FISSION
Subprogramme Area: An integrated approach to low dose risk research in Europe
Contract type:Networks of Excellence
homepage:
http://www.doremi-noe.net/
Coordinator:
SATEILYTURVAKESKUS
HELSINKI, FINLAND
Participants:
AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE,L'ENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILE , Italy
BUNDESAMT FUER STRAHLENSCHUTZ, Germany
COMMISSARIAT A L' ENERGIE ATOMIQUE, France
DUBLIN INSTITUTE OF TECHNOLOGY, Ireland
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM, Netherlands
FUNDACIO CENTRE DE RECERCA EN EPIDEMIOLOGIA AMBIENTAL - CREAL, Spain
HEALTH PROTECTION AGENCY HPA, United kingdom
HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH, Germany
INSTITUT CURIE, France
INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIRE, France
INSTITUTE FOR ENVIRONMENTAL SCIENCES ZAIDAN HOJIN, Japan
ISTITUTO SUPERIORE DI SANITA, taly
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN, Germany
NASJONALT FOLKEHELSEINSTITUTT, Norway
NORWEGIAN RADIATION PROTECTION AUTHORITY, Norway
STOCKHOLMS UNIVERSITET, Sweden
STUDIECENTRUM VOOR KERNENERGIE, Belgium
UNIVERSITA DEGLI STUDI DI PAVIA, Italy
UNIVERSITAETSKLINIKUM ERLANGEN, Germany
UNIVERSITETET FOR MILJO OG BIOVITENSKAP, Norway
UNIVERSITAET ROSTOCK, Germany
Subproject: Modulation of Inflammation by low and moderate dose ionizing Irradiation (ModInIR)
The main objective of the project is to analyse the immune modulatory properties of low and moderate radiation doses.
Contact:
Prof. Dr. med. G. Hildebrand
Universität Rostock
Klinik und Poliklinik für Strahlentherapie
Labor für Strahlenbiologie
Südring 75
18059 Rostock
Tel. +49-381-494-9110
Fax. +49-381-494-9002 www.strahlentherapie.med.uni-rostock.de/
|
|
|
Öffentlich finanzierte Forschungsprojekte 
für Projekte
uni-rostock.de
